one8zero8 LLC bought a new position in shares of Novartis AG (NYSE:NVS – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 2,864 shares of the company’s stock, valued at approximately $279,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Human Investing LLC bought a new stake in shares of Novartis in the 4th quarter worth approximately $25,000. Union Bancaire Privee UBP SA acquired a new position in Novartis in the fourth quarter worth approximately $27,000. Legacy Investment Solutions LLC bought a new position in shares of Novartis in the third quarter valued at $28,000. Kestra Investment Management LLC acquired a new stake in shares of Novartis during the 4th quarter valued at $47,000. Finally, Clearstead Trust LLC bought a new stake in shares of Novartis during the 4th quarter worth $51,000. 13.12% of the stock is currently owned by institutional investors.
Novartis Trading Up 0.0 %
Shares of NYSE:NVS opened at $109.15 on Monday. The firm has a fifty day moving average of $105.36 and a two-hundred day moving average of $107.59. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92. The firm has a market capitalization of $223.10 billion, a P/E ratio of 18.56, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53.
Novartis Dividend Announcement
The company also recently disclosed a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis’s dividend payout ratio is currently 42.69%.
Wall Street Analyst Weigh In
NVS has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft raised Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research note on Thursday, February 13th. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. Finally, HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Novartis has a consensus rating of “Hold” and an average target price of $123.38.
View Our Latest Stock Report on NVS
Novartis Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Recommended Stories
- Five stocks we like better than Novartis
- Stock Market Sectors: What Are They and How Many Are There?
- How to Build the Ultimate Everything ETF Portfolio
- What Are Dividends? Buy the Best Dividend Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Growth Stocks: What They Are, What They Are Not
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.